State Board of Administration of Florida Retirement System Has $36.92 Million Position in Iqvia Holdings Inc (NYSE:IQV)

State Board of Administration of Florida Retirement System increased its position in Iqvia Holdings Inc (NYSE:IQV) by 3.6% during the second quarter, HoldingsChannel reports. The institutional investor owned 229,477 shares of the medical research company’s stock after acquiring an additional 8,046 shares during the period. State Board of Administration of Florida Retirement System’s holdings in Iqvia were worth $36,923,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP lifted its holdings in shares of Iqvia by 10.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,458,539 shares of the medical research company’s stock valued at $169,413,000 after purchasing an additional 136,768 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Iqvia by 8.4% in the fourth quarter. Geode Capital Management LLC now owns 2,130,570 shares of the medical research company’s stock valued at $247,087,000 after purchasing an additional 164,811 shares in the last quarter. Pennsylvania Trust Co bought a new position in shares of Iqvia in the first quarter valued at approximately $1,733,000. Winslow Evans & Crocker Inc. lifted its holdings in shares of Iqvia by 95.2% in the first quarter. Winslow Evans & Crocker Inc. now owns 2,050 shares of the medical research company’s stock valued at $296,000 after purchasing an additional 1,000 shares in the last quarter. Finally, Conning Inc. lifted its holdings in shares of Iqvia by 3.6% in the first quarter. Conning Inc. now owns 2,600 shares of the medical research company’s stock valued at $374,000 after purchasing an additional 90 shares in the last quarter. Hedge funds and other institutional investors own 90.86% of the company’s stock.

NYSE:IQV traded down $0.18 during trading hours on Thursday, hitting $157.01. 3,679 shares of the company’s stock traded hands, compared to its average volume of 1,123,575. The firm has a market cap of $30.70 billion, a P/E ratio of 30.71, a P/E/G ratio of 1.91 and a beta of 0.88. Iqvia Holdings Inc has a 52 week low of $104.90 and a 52 week high of $164.13. The business’s fifty day simple moving average is $157.36 and its two-hundred day simple moving average is $144.52. The company has a quick ratio of 1.14, a current ratio of 1.14 and a debt-to-equity ratio of 1.72.

Iqvia (NYSE:IQV) last posted its quarterly earnings data on Wednesday, July 24th. The medical research company reported $1.39 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.38 by $0.01. The company had revenue of $2.74 billion during the quarter, compared to analyst estimates of $2.70 billion. Iqvia had a return on equity of 15.95% and a net margin of 2.31%. The firm’s quarterly revenue was up 6.7% on a year-over-year basis. During the same quarter last year, the company earned $1.29 earnings per share. On average, analysts expect that Iqvia Holdings Inc will post 5.87 EPS for the current year.

In related news, insider Kevin C. Knightly sold 6,945 shares of Iqvia stock in a transaction on Monday, July 29th. The stock was sold at an average price of $158.53, for a total transaction of $1,100,990.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Ari Bousbib sold 96,000 shares of Iqvia stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $160.00, for a total value of $15,360,000.00. The disclosure for this sale can be found here. Insiders have sold 198,945 shares of company stock valued at $30,860,991 in the last three months. 6.00% of the stock is owned by corporate insiders.

A number of analysts recently commented on the company. Stifel Nicolaus increased their price target on Iqvia from $167.00 to $178.00 and gave the company a “buy” rating in a research report on Wednesday, June 19th. William Blair reaffirmed an “outperform” rating on shares of Iqvia in a research report on Wednesday, June 19th. Zacks Investment Research raised Iqvia from a “sell” rating to a “hold” rating in a research report on Friday, May 3rd. Svb Leerink assumed coverage on Iqvia in a research report on Tuesday, May 28th. They set an “outperform” rating and a $160.00 price target for the company. Finally, SunTrust Banks increased their price target on Iqvia from $155.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. Three analysts have rated the stock with a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $161.13.

About Iqvia

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Read More: What is the strike price in options trading?

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.